Test Price
3,000 AEDโ Home Collection Available
Breast Comprehensive Panel Genetic Test in UAE | 3,000 AED
Executive Summary & Core Metrics
- โ Accuracy Guarantee: 99.9% diagnostic sensitivity achieved via ISO 9001:2015 accredited next-generation sequencing (NGS) with orthogonal variant confirmation.
- โ Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all seven emirates.
- โ Clinical Guidance: Complimentary post-test telephonic clinical guidance for result interpretation by a qualified genetic counsellor.
- โ Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Breast Comprehensive Panel Genetic Test is a clinically validated next-generation sequencing assay that simultaneously interrogates 30 high-penetrance hereditary cancer susceptibility genes โ including BRCA1, BRCA2, TP53, PTEN, PALB2, ATM, CHEK2, CDH1, STK11, and others โ to identify pathogenic germline variants associated with significantly elevated lifetime risk for breast, ovarian, pancreatic, and other syndromic malignancies. This test is indicated for individuals with a personal or family history of early-onset breast cancer, bilateral breast cancer, triple-negative breast cancer, multiple primary cancers, or known familial pathogenic variants. It empowers patients and clinicians to pursue risk-reducing strategies, enhanced surveillance protocols, and targeted therapeutic interventions aligned with DHA precision medicine guidelines.
Testing is performed on the Illumina NovaSeq 6000 platform with 500x mean depth, full exon and splice-site coverage, and alignment to the GRCh38 reference genome. Variants are classified per ACMG/AMP guidelines with ClinVar, gnomAD v4, and dbNSFP annotations.
| Feature | Our Test โ Breast Comprehensive NGS Panel | Closest Alternative โ Single-Gene / BRCA1+2 Only |
|---|---|---|
| Genes Analyzed | 30 Genes (ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2) | 2 Genes (BRCA1 + BRCA2 only) |
| Methodology | NGS with Full Exon & Splice-Site Coverage | 500x Mean Depth | GRCh38 Alignment | Sanger Sequencing or Limited PCR-Based Panels |
| Variant Classification | ACMG/AMP Guidelines with ClinVar, gnomAD v4, and dbNSFP annotations | ACMG 2015 Guidelines |
| Turnaround Time | 3 to 4 Weeks (Includes Confirmatory Orthogonal Validation) | 4 to 8 Weeks |
| Sample Types Accepted | Whole Blood (EDTA), Extracted DNA, or One-Drop Blood on FTA Card | Whole Blood Only |
| Price (UAE) | 3,000 AED | 1,500โ2,500 AED |
Genes Included in the Panel
The 30-gene panel covers all clinically actionable genes associated with hereditary breast and ovarian cancer (HBOC) syndrome, Li-Fraumeni syndrome, Cowden syndrome, hereditary diffuse gastric cancer, Lynch syndrome, Fanconi anemia pathway disorders, and other hereditary cancer predisposition syndromes recognised under DHA oncology guidelines.
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh โ Consultant Medical Genetics | DHA Registration ID: 9294403
"In my clinical practice across the UAE, I have observed how comprehensive multi-gene panel testing bridges critical gaps in hereditary cancer risk assessment. A negative BRCA-only test may provide false reassurance when a pathogenic variant in PALB2 or TP53 is the true driver. This 30-gene panel enables precise risk stratification, guiding evidence-based decisions for enhanced surveillance, chemoprevention, or prophylactic surgery. It is essential that these results are reviewed in consultation with a qualified genetic counsellor to ensure accurate interpretation and appropriate clinical action."
Medication & Clinical Management Advisory
โ Medication & Clinical Management Advisory
Do not discontinue any prescribed medication, hormone therapy, or surveillance regimen based solely on this genetic test result. Genetic findings must be interpreted within the full context of your personal medical history, family history, and current clinical status. Any modification to your treatment plan โ including initiation of risk-reducing medications such as tamoxifen or raloxifene โ must be undertaken only under direct supervision of your treating physician.
Exclusion Criteria & Emergency Red Flags
๐ฉ Exclusion Criteria โ This Test Is NOT Suitable For:
- Individuals under 18 years of age without court-authorised legal guardian consent (in accordance with UAE medical liability laws).
- Patients seeking emergency diagnosis of an active, palpable breast mass or acute clinical symptoms.
- Somatic tumour profiling (this is a germline/heritable test only).
- Individuals who have not undergone or declined pre-test genetic counselling.
- Non-consenting individuals or those unable to provide informed consent per UAE Personal Data Protection Law (PDPL) requirements.
๐จ Seek Immediate Emergency Care If You Experience:
- A new, rapidly growing, or painful breast lump.
- Bloody or spontaneous nipple discharge.
- Skin dimpling, peau d'orange, or nipple retraction of recent onset.
- Unexplained axillary swelling or lymphadenopathy.
- Constitutional symptoms: unintentional weight loss, night sweats, or persistent bone pain.
Do not wait for genetic test results. These symptoms require immediate clinical evaluation, imaging (mammography/ultrasound), and possible biopsy.
Patient FAQ & Clinical Guidance
1. What is the Breast Comprehensive Panel NGS test and who should consider it?
The Breast Comprehensive Panel Genetic Test detects pathogenic, likely pathogenic, and variants of uncertain significance across 30 clinically actionable hereditary cancer genes โ including BRCA1, BRCA2, TP53, PTEN, PALB2, ATM, CHEK2, CDH1, and STK11 โ using high-depth next-generation sequencing with full exon and splice-site coverage aligned to the GRCh38 reference genome. This test is clinically indicated for individuals with a personal history of early-onset breast cancer (diagnosed before age 50), triple-negative breast cancer, bilateral breast cancer, ovarian cancer at any age, male breast cancer, or a strong family history of breast, ovarian, pancreatic, or aggressive prostate cancer across multiple generations. It is also recommended for individuals of Ashkenazi Jewish ancestry or those with a known familial pathogenic variant seeking cascade testing.
2. How should I prepare for this test, and what does the pre-test genetic counselling involve?
Pre-test preparation requires a mandatory genetic counselling session โ conducted by a DHA-licensed genetic counsellor โ during which a detailed three-generation pedigree chart is constructed documenting all family members affected by cancers covered in the panel genes, including breast, ovarian, colorectal, endometrial, pancreatic, gastric, and thyroid malignancies, as well as ages at diagnosis and bilateral or multifocal disease patterns. No fasting or medication adjustments are required prior to sample collection; however, patients who have undergone allogeneic bone marrow transplantation should inform the laboratory as donor DNA may confound germline results. A clinical history form must be completed and submitted alongside the sample, detailing prior biopsies, hormone receptor status (if applicable), and any previous genetic testing results.
3. What happens after I receive my results, and what do the different result categories mean?
Post-test results are classified according to the ACMG/AMP five-tier system: Pathogenic (Class 5), Likely Pathogenic (Class 4), Variant of Uncertain Significance โ VUS (Class 3), Likely Benign (Class 2), and Benign (Class 1). A pathogenic or likely pathogenic finding triggers a structured post-test clinical guidance session wherein your referring oncologist or genetic counsellor outlines evidence-based risk management options, including enhanced breast MRI surveillance, risk-reducing mastectomy, chemoprevention with SERMs, or targeted screening for associated malignancies per NCCN and DHA guidelines. A VUS result is not clinically actionable and should not prompt prophylactic interventions; periodic reclassification monitoring is recommended as new population data emerge. All results are securely archived under UAE PDPL-compliant protocols, and cascade family testing can be arranged through our licensed network.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) governing genomic data privacy, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient genomic data is encrypted, pseudonymised, and stored within UAE-sovereign infrastructure. Clinical testing safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Cascade family testing and data-sharing requests require explicit written consent per UAE genetic privacy statutes.
Clinical & Logistical Metadata
| Test Name | Breast Comprehensive Panel Genetic Test (30-Gene NGS Panel) |
| Price (AED) | 3,000 AED |
| Turnaround Time | 3 to 4 Weeks (includes confirmatory orthogonal validation) |
| Sample Type / Matrix | Whole Blood (EDTA tube, 4โ6 mL), Extracted DNA (minimum 1 ยตg at โฅ50 ng/ยตL, A260/A280: 1.8โ2.0), or One-Drop Blood on FTA Card (fully dried, protected from contamination) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq 6000, 500x mean depth, full exon and splice-site coverage, GRCh38 alignment, variant classification per ACMG/AMP guidelines |
| ICD-10-CM Code | Z15.01, Z13.820 |
| LOINC Code | 96783-1 |
| DHA Facility License & Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians